Evaluating Rational Drug Use in Developing Countries: A Cross-Sectional Analysis of Prescribing Patterns Against WHO Indicators in Pakistan and Yemen

评估发展中国家的合理用药:巴基斯坦和也门处方模式与世卫组织指标的横断面分析

阅读:1

Abstract

The rational use of medications is essential for optimal healthcare delivery, especially in developing countries. This research delves into prescribing patterns within the healthcare system of Pakistan and Yemen against World Health Organization (WHO) prescribing indicators to uncover variances from recommended practices. A cross-sectional study was conducted in the outpatient department of different hospitals in Pakistan and Yemen, including 400 prescriptions. Demographic details and prescription data were collected, focusing on WHO prescribing indicators including the average number of drugs per encounter, the percentage of drugs prescribed by generic name, the percentage of drugs prescribed from the essential drug list, and the prevalence of antibiotic and injectable prescriptions. The mean age of patients was 43.54 ± 16.92 and 38.81 ± 18.67 years in Pakistan and Yemen, respectively. Polypharmacy was observed in both populations, with an average of 5.44 ± 1.16 drugs per encounter in Pakistan and 6.18 ± 1.09 in Yemen. Irrational antibiotic use was observed, with rates of 65% and 72.5% encounters in Pakistan and Yemen, respectively. The mean injectable medications per hospital were 28.5 (57%) and 34 (68%) in Pakistan and Yemen, respectively. In Pakistan, the mean percentage of generic prescribing was 74.18%, while in Yemen, it was 78.24%. The total percentage of drugs prescribed from the essential drug list was 98.24% in Pakistan, whereas 97.87% in Yemen. The findings reveal significant deviations from WHO prescribing indicators marked by polypharmacy and excessive antimicrobial and injectable utilization, which pose risks to patient safety and contribute to antimicrobial resistance.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。